Clinical trial
A Randomized Controlled Trial of Rivaroxaban Combined With Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone 1 Month After Drug-coated Balloon Angioplasty in Patients With Acute Coronary Syndrome Without High Bleeding Risk
NCT05750758 is registered in ClinicalTrials.gov with Henan Institute of Cardiovascular Epidemiology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Controlled Trial of Rivaroxaban Combined With Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone 1 Month After Drug-coated Balloon Angioplasty in Patients With Acute Coronary Syndrome Without High Bleeding Risk
- Lead sponsor
- Henan Institute of Cardiovascular Epidemiology
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 20, 2023
- Completion date
- December 1, 2023
- Enrollment
- 140 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.